Get started
Author

Robert Bruce Montgomery

Observed names: R. Bruce Montgomery, Robert B. Montgomery
OpenAlex ID: A5122952491
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
2026 · Deepak Kilari, Karla V. Ballman, et al. · Journal of Clinical Oncology · 1
Comparison of docetaxel triplet therapy with androgen receptor pathway inhibitor (ARPI) doublet in US veterans with metastatic hormone sensitive prostate cancer (mHSPC).
2026 · Abigail Chu, Molly Wynveen, et al. · Journal of Clinical Oncology · 1
PDF
Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer
2026 · Krishny Karunanandaa, Eric Marshall Knoche, et al. · The Oncologist · 1
Evolution and heterogeneity of lethal metastatic bladder cancer subtypes
2026 · Pushpa Itagi, Samantha L. Schuster, et al. · Nature
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer
2026 · Taylor B. Crawford, Maliha Tayeb, et al. · Journal of the National Comprehensive Cancer Network
PDF
Detection of mutational signatures in advanced cancer patients using clinical-grade specimens.
2026 · Samantha Rueckeis, Ryan Hausler, et al. · Journal of Clinical Oncology
Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
2026 · Ethan Lo, Daniel Sabath, et al. · Journal of Clinical Oncology
Homologous recombination repair (HRR) genes and overall survival prognosis within the STRATOS-P classification in metastatic hormone-sensitive prostate cancer (mHSPC).
2026 · Kara N. Maxwell, Martin W. Schoen, et al. · Journal of Clinical Oncology
Overall survival in veterans with metastatic hormone sensitive prostate cancer by initial therapy and STRATOS-P somatic tumor classification.
2026 · Robert Wilson, Abigail Chu, et al. · Journal of Clinical Oncology
PDF
STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.
2026 · Martin W. Schoen, Joshua Gruber, et al. · Journal of Clinical Oncology
Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer.
2026 · Martin W. Schoen, Jiannong Li, et al. · Journal of Clinical Oncology
Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
2026 · Candace Haghighi, Ethan Lo, et al. · Journal of Clinical Oncology
PDF
Feasibility and outcomes of response-adapted and retreatment 177 Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
2026 · Alireza Ghodsi, Ridvan A. Demirci, et al. · Journal of Clinical Oncology
PDF
Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
2026 · Robert Bruce Montgomery, Lauren Howard, et al. · Journal of Clinical Oncology
PDF
SPECTRA study: A phase II trial of supraphysiological androgen to enhance treatment activity with DNA-damaging agents in men with metastatic castration resistant prostate cancer (mCPRC).
2026 · Gabrielle Paras, Roman Gulati, et al. · Journal of Clinical Oncology
PDF
Duplex-Seq derived urinary cell-free DNA of Lynch syndrome patients with upper tract urothelial carcinoma.
2026 · Alex Zhu, Jonathan L. Wright, et al. · Journal of Clinical Oncology
PDF
Integration of genomic classification and clinical characteristics predicts survival in metastatic prostate cancer
2026 · Martin W. Schoen, Jiannong Li, et al. · medRxiv
PDF
Works count: 17
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type